Banque Pictet & Cie 13F: New $27M Stake in GENB

Banque Pictet & Cie disclosed a new position in Generate Biomedicines, Inc. (GENB) in a filing on October 16, 2026. The firm acquired 1,773,043 shares, valued at approximately $26.6 million. This marks Banque Pictet's first stake in the company, reflecting a significant move into the biotechnology sector.

What Changed in Banque Pictet's Position

Banque Pictet opened a new position in Generate Biomedicines with 1,773,043 shares. The investment represents a new stake for the firm, reflecting its interest in the company's potential in the healthcare sector.

Other Institutional Activity in Generate Biomedicines

Several other institutional investors have also made moves in Generate Biomedicines. Flagship Pioneering LLC holds 62,673,117 shares valued at about $757.7 million. FMR, LLC increased its stake by 1,004,170 shares, bringing its total to 5,221,599 shares valued at $63.1 million, a 23.8% increase. Capital World Investors added 211,422 shares for a total of 4,215,632 shares worth about $50.97 million, marking a 5.3% increase. Conversely, Braidwell LP reduced its holdings by 308,983 shares, ending with 3,283,844 shares valued at $39.7 million, an 8.6% decrease. Price (T. Rowe) Associates Inc. grew its stake by 47,044 shares, totaling 2,156,627 shares worth about $26.1 million, reflecting a 2.2% increase.

Generate Biomedicines, Inc. Stock Down 8.2%

The stock for Generate Biomedicines has recently traded around $11.99. This price is below both its 50-day moving average of about $15.41 and its 200-day average of approximately $14.12. The stock is also about 47.1% below its 52-week high of $22.67, but it trades 9% above its 52-week low of $11.00. The mean price target for the stock is $27, indicating potential upside even at current levels.

Recent Earnings

For the trailing twelve months, Generate Biomedicines reported revenue of about $26.5 million with a net margin of 0.0%, reflecting ongoing challenges in profitability. Its next earnings report is scheduled for November 5, 2026.

Insider Buying and Selling at Generate Biomedicines, Inc.

Insiders have recently been active at Generate Biomedicines. Noubar Boghos Afeyan, a director and beneficial owner, purchased 4,687,500 shares at an average price of $12.17, totaling about $57.0 million on March 2, 2026. Jane L. Mendillo, a director, acquired 1,500 shares at $16.00, valued at $24,000 on the same day. CEO Michael Nally bought 20,000 shares for $240,000 at $12.00 each on March 4, 2026. Conversely, Frances H. Ph.D. Arnold sold 1,000 shares at $16.00 for approximately $16,002 on September 1, 2026.

Analysts Set New Price Targets

On August 28, 2026, HC Wainwright & Co. maintained a Buy rating on Generate Biomedicines and raised its price target to $30. The firm reiterated this rating on September 8 and again on October 5, 2026, keeping the target stable at $30. The consensus among analysts is a strong buy, with a mean price target of $27 across five analyst opinions.

About Generate Biomedicines

Generate Biomedicines, Inc. specializes in drug discovery and development using machine learning and generative biology. The company focuses on creating novel protein therapeutics to address various medical needs. The new investment from Banque Pictet may signal confidence in Generate's innovative approaches within the biotechnology landscape.

Bottom Line

Investors should note that 13F filings reflect holdings as of the reporting period and may not represent current positions. With the next earnings date approaching on November 5, 2026, it will be crucial to watch how the company's financial performance unfolds in the coming quarters.